US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACRES Commercial Realty Corp.

17.15

-0.4100-2.33%

Post-market: 17.150.00000.00%16:05 EDT

Volume:32.29K

Turnover:562.41K

Market Cap:127.87M

PE:14.91

High:18.01

Open:17.75

Low:17.02

Close:17.56

Loading ...

Overview Company News Filings

ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program

Press Release: ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

ACRES Commercial Realty's (NYSE:ACR) investors will be pleased with their stellar 124% return over the last year

Simply Wall St.

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nektar presents preclinical data on NKTR-422 at ACR conference

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Acres Commercial Realty Corp : Raymond James Raises Target Price to $21 From $20

THOMSON REUTERS

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Press Release: Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease

Zacks Small Cap Research

Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","market":"US","secType":"STK","nameCN":"ACRES Commercial Realty Corp.","latestPrice":17.15,"timestamp":1744920000000,"preClose":17.56,"halted":0,"volume":32285,"hourTrading":{"tag":"盘后","latestPrice":17.15,"preClose":17.15,"latestTime":"16:05 EDT","volume":205,"amount":3515.75,"timestamp":1744920314974},"delay":0,"floatShares":7105800,"shares":7456150,"eps":1.149999,"marketStatus":"Market Closed","change":-0.41,"latestTime":"04-17 16:00:00 EDT","open":17.75,"high":18.01,"low":17.02,"amount":562405.7287,"amplitude":0.056378,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.149999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":17.56,"dividendRate":0.048105,"preHourTrading":{"tag":"盘前","latestPrice":17.25,"preClose":17.56,"latestTime":"08:25 EDT","volume":22,"amount":380.82,"timestamp":1744892710610},"postHourTrading":{"tag":"盘后","latestPrice":17.15,"preClose":17.15,"latestTime":"16:05 EDT","volume":205,"amount":3515.75,"timestamp":1744920314974},"volumeRatio":1.3680316586551644,"impliedVol":0.2225,"impliedVolPercentile":0.4622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","floatShares":7105800,"roa":"1.41%","roe":"6.41%","lyrEps":1.191983,"volumeRatio":1.3680316586551644,"shares":7456150,"dividePrice":0.825,"high":18.01,"amplitude":0.056378,"preClose":17.56,"low":17.02,"week52Low":12.33,"pbRate":"0.29","psRate":"1.62","week52High":23.81,"institutionHeld":0.1601,"latestPrice":17.15,"eps":1.149999,"divideRate":0.048105,"volume":32285,"delay":0,"ttmEps":1.149999,"open":17.75,"prevYearClose":16.15,"prevWeekClose":16.59,"prevMonthClose":21.67,"prevQuarterClose":21.67,"fiveDayClose":17.65,"twentyDayClose":23.38,"sixtyDayClose":17.96,"earningDate":1745942400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492484849","title":"ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2492484849","media":"PR Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492484849?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:16","pubTimestamp":1734642960,"startTime":"0","endTime":"0","summary":"The Company cannot predict when or if it will repurchase any shares of common and preferred stock and the timing and amount of any shares repurchased will be determined by the Company's management based on its evaluation of market conditions and other factors.This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, as amended. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as \"may,\" \"trend,\" \"will,\" \"continue,\" \"expect,\" \"intend,\" \"anticipate,\" \"estimate,\" \"believe,\" \"look forward\" or other similar words or terms. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from the expectations, intentions, beliefs, plans or predictions of the future expressed or implied by such forward-looking statements. Factors that can affect future results are discussed in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0_Ti4NbHR4TNJN3of8Rt2Q--~B/aD0xMzE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/15e66f387017d281d11350917bb934a1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0_Ti4NbHR4TNJN3of8Rt2Q--~B/aD0xMzE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/15e66f387017d281d11350917bb934a1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-reauthorizes-211600485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-reauthorizes-211600485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","ACR"],"gpt_icon":0},{"id":"2492731481","title":"Press Release: ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2492731481","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492731481?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:15","pubTimestamp":1734642900,"startTime":"0","endTime":"0","summary":"UNIONDALE, N.Y., Dec. 19, 2024 /PRNewswire/ -- ACRES Commercial Realty Corp.   announced today that its Board of Directors declared cash dividends on its Preferred Stock.The Company will pay a cash dividend on its 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock  in the amount of $0.6572606 per share, which reflects a rate of 10.51617%, equal to three-month Term SOFR on the dividend determination date plus a spread of 5.927% per annum. The floating rate period for dividends on the Series C Preferred Stock began on October 30, 2024. The dividend will be payable on January 30, 2025, to holders of record on January 2, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2486709932","title":"ACRES Commercial Realty's (NYSE:ACR) investors will be pleased with their stellar 124% return over the last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709932","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486709932?lang=en_us&edition=fundamental","pubTime":"2024-11-25 18:04","pubTimestamp":1732529054,"startTime":"0","endTime":"0","summary":"Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really flourishing, you can make more than 100%. For example, the ACRES Commercial Realty Corp.  share price had more than doubled in just one year - up 124%. In more good news, the share price has risen 10% in thirty days. We note that ACRES Commercial Realty reported its financial results recently; luckily, you can catch up on the latest revenue and profit numbers in our company report. The longer term returns have not been as good, with the stock price only 19% higher than it was three years ago.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.See our latest analysis for ACRES Commercial Realty. ACRES Commercial Realty went from making a loss to reporting a profit, in the last year.Please note, the market returns quoted in this article reflect the market weighted average","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2VvlHpnSNizANP3Yf_eUyQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a4c94a8040d73184f17dcbe251894407","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2VvlHpnSNizANP3Yf_eUyQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a4c94a8040d73184f17dcbe251894407"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-realtys-nyse-acr-100414350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NYSE","BK4110","ACR"],"gpt_icon":0},{"id":"2484793306","title":"Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484793306","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484793306?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:53","pubTimestamp":1731970380,"startTime":"0","endTime":"0","summary":"New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS  as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, Md. & EDMONTON, Alberta, November 18, 2024----Aurinia Pharmaceuticals Inc.   commends the American College of Rheumatology  for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis , which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function.The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelines suggest that steroids should be rapidly tapered to <5 mg/day by six months as the highest acceptable maintenance dose of steroids. The guidelines also call for achieving a proteinuria target of <0.5g/g urine protein creatinine ratio  by 12 months of treatment.The updated ACR guidelines for the diagnosis ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/An4d8dQutE8atJF9tsuxdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/531a63b034674830bd95dad02710306d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/An4d8dQutE8atJF9tsuxdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/531a63b034674830bd95dad02710306d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-commends-2024-updated-acr-225300348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","BK4007","CNI","ACB","BK4016","AUPH","BK4557","ACR","BK4139"],"gpt_icon":1},{"id":"2484986700","title":"Nektar presents preclinical data on NKTR-422 at ACR conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2484986700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484986700?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:50","pubTimestamp":1731963036,"startTime":"0","endTime":"0","summary":"Nektar (NKTR) announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology, or ACR, confe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-presents-preclinical-data-on-nktr-422-at-acr-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-presents-preclinical-data-on-nktr-422-at-acr-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4110","NKTR","BK4007","ACR"],"gpt_icon":0},{"id":"2484985090","title":"Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484985090","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484985090?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:30","pubTimestamp":1731961800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics  today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology conference, being held in Washington, D.C. from November 14-19, 2024.Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin , is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-presents-first-preclinical-203000192.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-presents-first-preclinical-203000192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4110","BK4007","LU1169590202.USD","LU1169589451.USD","BK4218","PD","NKTR","CSF","BK4181","ACR","PK","BK4107","BK4023","BK4117"],"gpt_icon":0},{"id":"2484562620","title":"Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484562620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484562620?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:30","pubTimestamp":1731936600,"startTime":"0","endTime":"0","summary":"ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger Technology Enables ALLO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982777/0/en/Allogene-Therapeutics-Presents-Preclinical-Data-for-ALLO-329-an-Allogeneic-CD19-CD70-Dual-CAR-T-for-the-Treatment-of-Autoimmune-Disease-at-the-American-College-of-Rheumatology-ACR-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLO","BK4077","BK4117","TRAC","AFG","ACR","BK4110","BK4149","BK4112","BK4022","BK4230","BK4505","SLE","MLR","BK4107","CAR"],"gpt_icon":0},{"id":"2484622908","title":"Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622908","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622908?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:05","pubTimestamp":1731935100,"startTime":"0","endTime":"0","summary":"27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982757/24675/en/Fate-Therapeutics-Presents-6-Month-Follow-up-Data-on-First-Patient-Treated-in-Phase-1-Autoimmunity-Study-with-Fludarabine-free-Conditioning-and-FT819-Off-the-shelf-1XX-CAR-T-cell-P.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","BK4109","BK4110","CAR","CRS","IE0031619046.USD","IE00B66KJ199.SGD","SLE","BK4006","IE00B7SZL793.SGD","BK4022","BK4139","FATE","IE00B19Z4B17.USD","BK4077","ACR","BK4230"],"gpt_icon":1},{"id":"2484521622","title":"Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484521622","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484521622?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemotherapy Initial Phase 1 Clinical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982736/24675/en/Fate-Therapeutics-Highlights-FT522-Off-the-shelf-ADR-armed-CAR-NK-Cell-Product-Candidate-at-2024-ACR-Convergence.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SD","BK4110","IE00B19Z4B17.USD","CAR","CRS","PK","BK4213","IE00B66KJ199.SGD","PR","CR","ACR","BK4077","BK4181","BK4218","BK4139","IE00B7SZL793.SGD","IE0031619046.USD","BK4022","BK4161","SLE","BK4006","BK4230","FATE"],"gpt_icon":1},{"id":"2484218166","title":"Acres Commercial Realty Corp : Raymond James Raises Target Price to $21 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2484218166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484218166?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:32","pubTimestamp":1731933151,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACR","BK4110"],"gpt_icon":0},{"id":"2484626188","title":"Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626188","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626188?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event –。– All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period –。– Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional nave B cell repopulation as early as eight weeks in the first two patients –。– 40 U.S. clinical sites actively recruiting across the RESET clinical development program, with 16 patients enrolled and 10 patients dosed with CABA-201 as of November 12, 2024 –","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-presents-positive-clinical-120000795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","ACR","SLE","IE0031619046.USD","IMNM","BK4139","BK4077","BK4006","BK4161","CRS","DM","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4563","BK4546","CABA","BK4110"],"gpt_icon":1},{"id":"2484589626","title":"Press Release: Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2484589626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484589626?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology  Convergence 2024 Annual Meeting. Poster presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL  treatment demonstrating statistically significant improvement in primary endpoint of fibromyalgia nociplastic pain and in all six key secondary endpoints, including sleep quality. New Drug Application  submitted to FDA in October 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025. TNX-102 SL is a potential non-opioid analgesic targeting non-restorative sleep. Tonix submitted a new drug application  to the U.S. Food and Drug Administration  in October 2024 for TNX-102 SL for the management of fibromyalgia. The FDA typically has a 60-day filing review period to determine whether the submitted NDA is complete and ac","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","TNXP","BK4583","CNS","BK4117","BK4139","BK4110","AFG","ACR","BK4135"],"gpt_icon":1},{"id":"2483514693","title":"Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483514693","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483514693?lang=en_us&edition=fundamental","pubTime":"2024-11-16 22:00","pubTimestamp":1731765600,"startTime":"0","endTime":"0","summary":"-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue. -Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases. REDWOOD CITY, Calif. & BOSTON, November 16, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Convergence 2024 in Washington, D.C., November 14-19.Concurrent with ADI-001 tissue trafficking and activation, complete depl","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Rye59Ues0jMwXKyZll4xfA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Rye59Ues0jMwXKyZll4xfA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-presents-clinical-biomarker-140000237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","BK4022","BK4117","SLE","BK4107","BK4077","BK4230","BK4139","IIM","ACR","AFG","BK4110","ACET"],"gpt_icon":0},{"id":"2483890015","title":"PLX: Self-Sustaining Rise to Lead in Renal Rare Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2483890015","media":"Zacks Small Cap Research","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483890015?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:12","pubTimestamp":1731679920,"startTime":"0","endTime":"0","summary":"Protalix Biotherapeutics, Inc.  announced third quarter 2024 financial and operational results in a November 14th, 2024  press release  and in the filing of  Form 10-Q  . The reports were followed by a conference call which discussed recent achievements, clinical updates and financial performance. Since the second quarter update, Protalix has repaid its convertible debt and completed the eighth cohort of its Phase I PRX-115 trial in gout. With preliminary results presented at the American College of Rheumatology conference, and a Phase II planned for 2H:25, we have increased visibility on this product over the next year or so. Revenues were impressive with a 74% increase driven by a strong increase in Chiesi revenues.The cash and equivalents balance on September 30, 2024 totaled $27.4 million versus $44.6 million at the end of 2023. Compared to the second quarter, cash fell by $17.6 million due to the repayment of the convertible note of  million offset by free cash flow gener","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eaAiSYPfau7nUscU63Gjdw--~B/aD0xMDYyO3c9MTc4NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/1995d2f223dbace09bdd2415d9824dcc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eaAiSYPfau7nUscU63Gjdw--~B/aD0xMDYyO3c9MTc4NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/scr.zacks.com/1995d2f223dbace09bdd2415d9824dcc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plx-self-sustaining-rise-lead-141200581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLX","BK4023","LU1169590202.USD","BK4218","ACR","BK4139","PD","LU1169589451.USD","BK4181","PK","BK4110"],"gpt_icon":0},{"id":"2483321924","title":"Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483321924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483321924?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:35","pubTimestamp":1731670548,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early detection...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupus-nephritis-breakthroughs-at-acr-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupus-nephritis-breakthroughs-at-acr-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACR","BK4139","AUPH","BK4110"],"gpt_icon":0},{"id":"2483257393","title":"Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483257393","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483257393?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:00","pubTimestamp":1731668400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, November 15, 2024----Aurinia Pharmaceuticals Inc.  , announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence  2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis , a serious manifestation of systemic lupus erythematosus , and reinforce the clinical importance of LUPKYNIS , a second generation calcineurin inhibitor , for the treatment of adults with active LN.An analysis from the Phase 3 AURORA 1 and 2 studies highlighted the long-term efficacy of LUPKYNIS in people with LN. This study focused on a new efficacy endpoint, sustained complete renal response , defined by the United States Food and Drug Administration  as achieving a complete renal response  at 12 months in AURORA 1 and at all study visits in the 2-year AURORA 2 continuation study. Significantly more LUPKYNIS patients achieved SCRR compared to patients ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-presents-data-underscoring-critical-110000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4557","ACR","BK4139","BK4016","AFG","AUPH","BK4007","BK4117","BK4110","CNI","SLE","ACB","BK4107"],"gpt_icon":1},{"id":"2483258337","title":"Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483258337","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483258337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981606/0/en/Alumis-Presents-Data-Highlighting-ESK-001-s-Potential-as-a-High-efficacy-Oral-Treatment-for-Systemic-Lupus-Erythematosus-SLE-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4110","BK4077","BK4007","ALMS","ACR"],"gpt_icon":0},{"id":"2483337338","title":"Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337338?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:02","pubTimestamp":1731618120,"startTime":"0","endTime":"0","summary":"– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –。Kronos Bio has been exploring the utility of KB-7898, a p300 KAT inhibitor, for autoimmune indications given the role of interferon regulatory factor 4  and p300 in B cells, T cells and other immune cells. The data demonstrates the ability of p300 KAT inhibition to modulate the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases.In the presentation titled, \"p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines\", the presenter, Dr. Peter Rahl, Vice President, Discovery Biology at Kronos, will summarize the experiments that led to the following key findings:. In ex vivo primary cell models, the authors demonstrated that p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ijRT4XFYumx4aXQz_S.WiQ--~B/aD0xOTM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/306fc5d57d77b3786b01ca1e604f81cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ijRT4XFYumx4aXQz_S.WiQ--~B/aD0xOTM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/306fc5d57d77b3786b01ca1e604f81cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kronos-bio-highlights-preclinical-data-210200776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KRO","BK4110","BK4090","ACR","KRON","BK4162","CIA","BK4505","BK4139"],"gpt_icon":0},{"id":"2483332212","title":"AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332212","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332212?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:00","pubTimestamp":1731618000,"startTime":"0","endTime":"0","summary":"MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA asthe First Potential Treatment tor IgG4-RD. Phase 4 AGILE Data Support Shortening KRYSTEXXA Infusion Time. THOUSAND OAKS, Calif., Nov. 14, 2024 /PRNewswire/ -- Amgen  today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology  Convergence 2024 conference in Washington, D.C., Nov. 14-19, 2024. New data showcase reduction in disease activityby UPLIZNA  in Immunoglobulin G4-Related Disease  and support shorter infusion times for KRYSTEXXA co-administered with weekly oral methotrexate 15 mg.\"These data add to the growing body of evidence for UPLIZNA and KRYSTEXXA and strengthen our commitment to developing new treatment options for rare diseases like IgG4-RD and uncontrolled gout,\" said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. \"Patients living with these debilitating conditions dese","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-presents-data-across-rare-210000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","IE00BFTCPJ56.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","BK4581","LU2112291526.USD","ACR","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","BK4585","BK4110","LU0320765992.SGD","LU0109394709.USD","RARE","IE0002141913.USD","LU0289739699.SGD","LU1057294990.SGD","SG9999001440.SGD","BK4588","LU1023059063.AUD","BK4533","LU1571399168.USD","LU2242652126.USD","BK4566","LU1061106388.HKD","LU0058720904.USD","LU1983299246.USD","LU0889565916.HKD","LU2242646821.SGD","AMGN","PML","LU0868494617.USD"],"gpt_icon":0},{"id":"2483670807","title":"Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483670807","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483670807?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596460,"startTime":"0","endTime":"0","summary":"Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis  Treated With KYV-101 Target Dose. KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed. Also at ACR Convergence 2024, Kyverna will present data on next-generation approaches, most notably with a poster on Ingenui-T, the Company's preclinical 3-day manufacturing process using autologous whole blood as starting material. Ingenui-T is designed to improve the patient experience by eliminating apheresis, leading to a potential for improved convenience, access and overall cost reduction. As the poster highlights, drug product from the Ingenui-T process manufactured with whol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/W4PdMGzxR8LSOetGHBXf6Q--~B/aD0yMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/51c107a1cce9fe9862ec80c3d9111c66"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kyverna-therapeutics-announces-patient-data-150100844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","ACR","BK4110","KYTX","BK4022","SLE","BK4139","CAR","BK4230"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":86,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACR\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":null,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"market":"US","date":"2025-03-05","symbol":"ACR","fiscalQuarterEnding":"2024/12","expectedEps":0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741150800000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-10-30","symbol":"ACR","fiscalQuarterEnding":"2024/09","expectedEps":0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730260800000,"reportTimeType":"post","actualEps":0.14},{"date":"2024-07-31","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.28,"defaultRemindTime":1722456000000,"name":null,"time":"Post Market","dateTimestamp":1722398400000,"actualEps":null},{"date":"2024-05-01","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":0.35,"defaultRemindTime":1714593600000,"name":null,"time":"Post Market","dateTimestamp":1714536000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACR\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-28","value":0.16,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-28","value":0.64,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-28","value":0.42,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-28","value":0.42,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-28","value":0.42,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1728360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACR","date":"2025-04-17","current":4.12892,"percent":0.519512,"low":-0.830359,"twenty":-0.28285,"median":3.878196,"eighty":5.926495,"high":14.204017,"avg":3.828385,"sd":3.113542,"marketCap":120841106},"quantilePoints":[{"date":"2020-04-24","current":2.005756,"twenty":2.42011,"median":4.35808,"eighty":23.688452,"marketCap":72139024},{"date":"2020-05-01","current":2.391384,"twenty":2.417668,"median":4.354063,"eighty":23.644331,"marketCap":86008529},{"date":"2020-05-08","current":-0.476126,"twenty":2.408405,"median":4.354063,"eighty":23.64292,"marketCap":80316788},{"date":"2020-05-15","current":-0.385121,"twenty":2.399108,"median":4.34603,"eighty":23.635049,"marketCap":64965358},{"date":"2020-05-22","current":-0.385121,"twenty":2.391757,"median":4.34603,"eighty":23.624215,"marketCap":64965358},{"date":"2020-05-29","current":-0.375728,"twenty":2.375238,"median":4.342013,"eighty":23.616544,"marketCap":63380838},{"date":"2020-06-05","current":-0.537291,"twenty":2.268298,"median":4.337996,"eighty":23.60285,"marketCap":90634598},{"date":"2020-06-12","current":-0.572985,"twenty":2.233131,"median":4.327955,"eighty":23.60285,"marketCap":96655777},{"date":"2020-06-19","current":-0.49784,"twenty":2.128917,"median":4.313896,"eighty":23.595809,"marketCap":83979610},{"date":"2020-06-26","current":-0.482811,"twenty":1.847407,"median":4.307872,"eighty":23.582109,"marketCap":81444376},{"date":"2020-07-02","current":-0.452752,"twenty":1.820352,"median":4.29783,"eighty":23.582109,"marketCap":76373909},{"date":"2020-07-10","current":-0.447117,"twenty":1.812445,"median":4.281763,"eighty":23.567545,"marketCap":75423197},{"date":"2020-07-17","current":-0.454631,"twenty":1.79588,"median":4.247621,"eighty":23.561875,"marketCap":76690813},{"date":"2020-07-24","current":-0.450874,"twenty":1.778891,"median":4.229546,"eighty":23.561368,"marketCap":76057005},{"date":"2020-07-31","current":-0.418937,"twenty":1.77303,"median":4.197413,"eighty":23.561368,"marketCap":70669634},{"date":"2020-08-07","current":-0.389478,"twenty":1.767642,"median":4.169297,"eighty":23.561368,"marketCap":82171619},{"date":"2020-08-14","current":-0.373121,"twenty":1.763277,"median":4.142325,"eighty":23.555746,"marketCap":78720623},{"date":"2020-08-21","current":-0.356571,"twenty":1.753473,"median":4.14118,"eighty":23.545397,"marketCap":75228983},{"date":"2020-08-28","current":-0.353562,"twenty":1.748369,"median":4.135155,"eighty":23.541135,"marketCap":74594139},{"date":"2020-09-04","current":-0.330994,"twenty":1.739311,"median":4.12913,"eighty":23.540628,"marketCap":69832811},{"date":"2020-09-11","current":-0.321967,"twenty":1.735731,"median":4.11708,"eighty":23.528183,"marketCap":67928280},{"date":"2020-09-18","current":-0.315949,"twenty":1.729507,"median":4.088963,"eighty":23.515678,"marketCap":66658592},{"date":"2020-09-25","current":-0.303913,"twenty":1.724061,"median":4.08093,"eighty":23.512872,"marketCap":64119217},{"date":"2020-10-02","current":-0.335508,"twenty":1.721155,"median":4.062855,"eighty":23.505565,"marketCap":70785077},{"date":"2020-10-09","current":-0.349048,"twenty":1.709118,"median":4.024697,"eighty":23.499765,"marketCap":73641873},{"date":"2020-10-16","current":-0.314444,"twenty":1.6899,"median":3.49084,"eighty":23.48763,"marketCap":66341170},{"date":"2020-10-23","current":-0.303913,"twenty":1.680487,"median":2.92946,"eighty":23.479024,"marketCap":64119217},{"date":"2020-10-30","current":-0.28285,"twenty":1.671636,"median":2.901471,"eighty":23.474204,"marketCap":59675311},{"date":"2020-11-06","current":-0.317044,"twenty":1.669001,"median":2.893012,"eighty":23.46316,"marketCap":68283910},{"date":"2020-11-13","current":-0.410817,"twenty":1.660341,"median":2.891803,"eighty":23.457665,"marketCap":88480560},{"date":"2020-11-20","current":-0.482264,"twenty":1.638881,"median":2.890595,"eighty":23.453467,"marketCap":103868483},{"date":"2020-11-27","current":-0.55371,"twenty":1.628025,"median":2.888178,"eighty":23.445171,"marketCap":119256407},{"date":"2020-12-04","current":-0.614737,"twenty":1.126039,"median":2.87972,"eighty":23.434129,"marketCap":132400258},{"date":"2020-12-11","current":-0.584968,"twenty":-0.285558,"median":2.864009,"eighty":23.429934,"marketCap":125988623},{"date":"2020-12-18","current":-0.580502,"twenty":-0.300302,"median":2.849508,"eighty":23.424434,"marketCap":125026878},{"date":"2020-12-24","current":-0.601341,"twenty":-0.300904,"median":2.831381,"eighty":23.416184,"marketCap":129515022},{"date":"2020-12-31","current":-0.593899,"twenty":-0.303913,"median":2.820506,"eighty":23.416184,"marketCap":127912114},{"date":"2021-01-08","current":-0.640041,"twenty":-0.314444,"median":2.798754,"eighty":23.409199,"marketCap":137850148},{"date":"2021-01-15","current":-0.596876,"twenty":-0.317044,"median":2.779419,"eighty":23.409199,"marketCap":128553277},{"date":"2021-01-22","current":-0.626645,"twenty":-0.321601,"median":2.768543,"eighty":23.407301,"marketCap":134964912},{"date":"2021-01-29","current":-0.59241,"twenty":-0.325277,"median":2.721413,"eighty":23.39772,"marketCap":127591532},{"date":"2021-02-05","current":-0.59241,"twenty":-0.327985,"median":2.702078,"eighty":23.395443,"marketCap":127591532},{"date":"2021-02-12","current":-0.601341,"twenty":-0.329791,"median":2.692411,"eighty":23.395443,"marketCap":129515022},{"date":"2021-02-19","current":-0.538901,"twenty":-0.336712,"median":2.68516,"eighty":23.382999,"marketCap":116066912},{"date":"2021-02-26","current":-0.585684,"twenty":-0.343632,"median":2.668242,"eighty":23.374703,"marketCap":126142837},{"date":"2021-03-05","current":-0.656758,"twenty":-0.34965,"median":2.65374,"eighty":23.37052,"marketCap":141450494},{"date":"2021-03-12","current":-0.765058,"twenty":-0.355066,"median":2.642864,"eighty":23.367731,"marketCap":151261945},{"date":"2021-03-19","current":-0.773314,"twenty":-0.359667,"median":2.636822,"eighty":23.366463,"marketCap":152894262},{"date":"2021-03-26","current":-0.730698,"twenty":-0.372029,"median":2.628363,"eighty":23.358624,"marketCap":144468510},{"date":"2021-04-01","current":-0.728783,"twenty":-0.374023,"median":2.619904,"eighty":23.353962,"marketCap":144089825},{"date":"2021-04-09","current":-0.733571,"twenty":-0.377896,"median":2.605403,"eighty":23.351176,"marketCap":145036538},{"date":"2021-04-16","current":-0.733507,"twenty":-0.38625,"median":2.600569,"eighty":23.341486,"marketCap":145023804},{"date":"2021-04-23","current":-0.728759,"twenty":-0.394383,"median":2.571519,"eighty":23.333221,"marketCap":144085138},{"date":"2021-04-30","current":-0.716127,"twenty":-0.403156,"median":2.562972,"eighty":23.333221,"marketCap":141587548},{"date":"2021-05-07","current":12.280556,"twenty":-0.403908,"median":2.564193,"eighty":23.325539,"marketCap":145696522},{"date":"2021-05-14","current":11.159187,"twenty":-0.403156,"median":2.571519,"eighty":23.313402,"marketCap":132392591},{"date":"2021-05-21","current":12.000214,"twenty":-0.401278,"median":2.600569,"eighty":23.309699,"marketCap":142370539},{"date":"2021-05-28","current":12.008001,"twenty":-0.399569,"median":2.605403,"eighty":23.297233,"marketCap":142462928},{"date":"2021-06-04","current":12.880178,"twenty":-0.397861,"median":2.619904,"eighty":23.282034,"marketCap":152810430},{"date":"2021-06-11","current":13.61997,"twenty":-0.394449,"median":2.629572,"eighty":23.269611,"marketCap":161587329},{"date":"2021-06-18","current":13.253968,"twenty":-0.393243,"median":2.638031,"eighty":23.261298,"marketCap":157245073},{"date":"2021-06-25","current":13.191669,"twenty":-0.389358,"median":2.644073,"eighty":23.248872,"marketCap":156505966},{"date":"2021-07-02","current":12.545324,"twenty":-0.388504,"median":2.655244,"eighty":23.240563,"marketCap":148837728},{"date":"2021-07-09","current":12.958051,"twenty":-0.387002,"median":2.668242,"eighty":23.229518,"marketCap":153734314},{"date":"2021-07-16","current":12.630985,"twenty":-0.385121,"median":2.68516,"eighty":23.229518,"marketCap":149854001},{"date":"2021-07-23","current":12.919114,"twenty":-0.385121,"median":2.696036,"eighty":23.229518,"marketCap":153272372},{"date":"2021-07-30","current":13.627758,"twenty":-0.378951,"median":2.704495,"eighty":23.222589,"marketCap":161679717},{"date":"2021-08-06","current":2.692645,"twenty":-0.378071,"median":2.712954,"eighty":23.210305,"marketCap":158604894},{"date":"2021-08-13","current":2.590862,"twenty":-0.377634,"median":2.699661,"eighty":23.201855,"marketCap":152609520},{"date":"2021-08-20","current":2.612452,"twenty":-0.375728,"median":2.692528,"eighty":23.188037,"marketCap":153881266},{"date":"2021-08-27","current":2.524548,"twenty":-0.374625,"median":2.68516,"eighty":23.18112,"marketCap":148703443},{"date":"2021-09-03","current":2.529174,"twenty":-0.374625,"median":2.668242,"eighty":23.18112,"marketCap":148975960},{"date":"2021-09-10","current":2.444355,"twenty":-0.373422,"median":2.655244,"eighty":23.164533,"marketCap":143979815},{"date":"2021-09-17","current":2.424306,"twenty":-0.373121,"median":2.644073,"eighty":23.160386,"marketCap":142798908},{"date":"2021-09-24","current":2.478282,"twenty":-0.372318,"median":2.638031,"eighty":23.160386,"marketCap":145978273},{"date":"2021-10-01","current":2.530717,"twenty":-0.372,"median":2.630356,"eighty":23.160386,"marketCap":149066799},{"date":"2021-10-08","current":2.432017,"twenty":-0.36928,"median":2.624738,"eighty":23.127211,"marketCap":143253103},{"date":"2021-10-15","current":2.422764,"twenty":-0.367258,"median":2.617487,"eighty":23.118917,"marketCap":142708069},{"date":"2021-10-22","current":2.422764,"twenty":-0.362252,"median":2.608928,"eighty":23.109059,"marketCap":142708069},{"date":"2021-10-29","current":2.421222,"twenty":-0.359194,"median":2.602389,"eighty":23.099865,"marketCap":142617230},{"date":"2021-11-05","current":2.948349,"twenty":-0.357001,"median":2.601479,"eighty":23.065008,"marketCap":135081545},{"date":"2021-11-12","current":2.972158,"twenty":-0.356571,"median":2.605403,"eighty":23.045624,"marketCap":136172379},{"date":"2021-11-19","current":2.906683,"twenty":-0.355367,"median":2.614969,"eighty":23.037354,"marketCap":133172587},{"date":"2021-11-26","current":2.84716,"twenty":-0.355066,"median":2.621242,"eighty":23.035979,"marketCap":130445503},{"date":"2021-12-03","current":2.698354,"twenty":-0.354164,"median":2.629572,"eighty":23.023539,"marketCap":123627794},{"date":"2021-12-10","current":2.672561,"twenty":-0.353562,"median":2.636203,"eighty":23.015245,"marketCap":122446058},{"date":"2021-12-17","current":2.432487,"twenty":-0.351757,"median":2.629572,"eighty":23.015245,"marketCap":111446820},{"date":"2021-12-23","current":2.45828,"twenty":-0.349951,"median":2.622321,"eighty":23.001399,"marketCap":112628556},{"date":"2021-12-31","current":2.474153,"twenty":-0.348446,"median":2.614969,"eighty":22.97803,"marketCap":113355779},{"date":"2022-01-07","current":2.45828,"twenty":-0.34634,"median":2.605403,"eighty":22.973988,"marketCap":112628556},{"date":"2022-01-14","current":2.628911,"twenty":-0.344535,"median":2.605403,"eighty":22.973776,"marketCap":120446196},{"date":"2022-01-21","current":2.41463,"twenty":-0.344234,"median":2.601479,"eighty":22.969629,"marketCap":110628695},{"date":"2022-01-28","current":2.329315,"twenty":-0.342428,"median":2.593946,"eighty":22.948894,"marketCap":106719875},{"date":"2022-02-04","current":2.416614,"twenty":-0.33972,"median":2.588548,"eighty":22.928309,"marketCap":110719598},{"date":"2022-02-11","current":2.402726,"twenty":-0.338517,"median":2.584693,"eighty":22.90988,"marketCap":110083278},{"date":"2022-02-18","current":2.333283,"twenty":-0.337915,"median":2.570395,"eighty":22.898273,"marketCap":106901681},{"date":"2022-02-25","current":2.245983,"twenty":-0.335508,"median":2.564193,"eighty":22.890838,"marketCap":102901958},{"date":"2022-03-04","current":3.243244,"twenty":-0.330994,"median":2.564193,"eighty":22.871107,"marketCap":110020560},{"date":"2022-03-11","current":3.039484,"twenty":-0.330994,"median":2.570395,"eighty":22.849369,"marketCap":103108427},{"date":"2022-03-18","current":3.155514,"twenty":-0.32949,"median":2.584693,"eighty":22.828635,"marketCap":107044517},{"date":"2022-03-25","current":3.422888,"twenty":-0.32949,"median":2.588548,"eighty":22.828635,"marketCap":116114636},{"date":"2022-04-01","current":3.397664,"twenty":-0.328951,"median":2.593946,"eighty":22.827656,"marketCap":115258964},{"date":"2022-04-08","current":3.274067,"twenty":-0.327985,"median":2.601479,"eighty":22.8079,"marketCap":111066173},{"date":"2022-04-14","current":3.248843,"twenty":-0.327985,"median":2.605403,"eighty":22.791313,"marketCap":110210502},{"date":"2022-04-22","current":3.127915,"twenty":-0.327985,"median":2.612452,"eighty":22.72819,"marketCap":106108277},{"date":"2022-04-29","current":2.868089,"twenty":-0.326782,"median":2.621242,"eighty":22.688706,"marketCap":97294170},{"date":"2022-05-06","current":4.375842,"twenty":-0.326481,"median":2.628911,"eighty":22.657479,"marketCap":100429958},{"date":"2022-05-13","current":4.21343,"twenty":-0.325277,"median":2.630625,"eighty":22.634624,"marketCap":96702425},{"date":"2022-05-20","current":3.735933,"twenty":-0.322569,"median":2.636822,"eighty":22.60654,"marketCap":85743401},{"date":"2022-05-27","current":3.743573,"twenty":-0.321967,"median":2.642864,"eighty":22.591302,"marketCap":85918746},{"date":"2022-06-03","current":3.785593,"twenty":-0.321967,"median":2.651324,"eighty":22.545587,"marketCap":86883140},{"date":"2022-06-10","current":3.678634,"twenty":-0.321692,"median":2.668242,"eighty":22.48538,"marketCap":84428318},{"date":"2022-06-17","current":3.224057,"twenty":-0.320881,"median":2.67161,"eighty":22.421163,"marketCap":73995328},{"date":"2022-06-24","current":3.193497,"twenty":-0.319259,"median":2.686797,"eighty":22.367371,"marketCap":73293950},{"date":"2022-07-01","current":3.304276,"twenty":-0.317289,"median":2.691936,"eighty":22.325763,"marketCap":75836444},{"date":"2022-07-08","current":3.227877,"twenty":-0.316825,"median":2.692645,"eighty":22.317329,"marketCap":74083000},{"date":"2022-07-15","current":2.998678,"twenty":-0.315949,"median":2.699661,"eighty":22.30517,"marketCap":68822669},{"date":"2022-07-22","current":3.055978,"twenty":-0.315949,"median":2.704495,"eighty":22.284437,"marketCap":70137752},{"date":"2022-07-29","current":3.174397,"twenty":-0.315648,"median":2.716828,"eighty":22.263703,"marketCap":72855589},{"date":"2022-08-05","current":5.232925,"twenty":-0.314444,"median":2.726247,"eighty":22.238823,"marketCap":77625212},{"date":"2022-08-12","current":5.466621,"twenty":-0.314444,"median":2.760853,"eighty":22.205649,"marketCap":81091851},{"date":"2022-08-19","current":5.438471,"twenty":-0.312338,"median":2.772168,"eighty":22.201502,"marketCap":80674282},{"date":"2022-08-26","current":5.815674,"twenty":-0.303913,"median":2.785945,"eighty":22.182759,"marketCap":86269703},{"date":"2022-09-02","current":5.460991,"twenty":-0.303612,"median":2.798754,"eighty":22.174132,"marketCap":81008337},{"date":"2022-09-09","current":5.427211,"twenty":-0.302408,"median":2.815672,"eighty":22.174132,"marketCap":80507255},{"date":"2022-09-16","current":5.179496,"twenty":-0.300904,"median":2.822922,"eighty":22.164182,"marketCap":76832650},{"date":"2022-09-23","current":4.898002,"twenty":-0.300904,"median":2.831036,"eighty":22.164182,"marketCap":72656962},{"date":"2022-09-30","current":4.588358,"twenty":-0.300904,"median":2.842292,"eighty":22.164182,"marketCap":68063706},{"date":"2022-10-07","current":4.802294,"twenty":-0.300904,"median":2.861593,"eighty":22.122715,"marketCap":71237228},{"date":"2022-10-14","current":4.644657,"twenty":-0.300904,"median":2.866049,"eighty":22.122715,"marketCap":68898843},{"date":"2022-10-21","current":4.802294,"twenty":-0.299399,"median":2.878511,"eighty":22.101982,"marketCap":71237228},{"date":"2022-10-28","current":5.731225,"twenty":-0.297895,"median":2.885762,"eighty":22.101982,"marketCap":85016997},{"date":"2022-11-04","current":5.658037,"twenty":-0.294886,"median":2.890595,"eighty":22.081248,"marketCap":83931318},{"date":"2022-11-11","current":3.269547,"twenty":-0.287363,"median":2.891803,"eighty":22.060514,"marketCap":82896095},{"date":"2022-11-18","current":3.224437,"twenty":-0.28285,"median":2.893012,"eighty":22.039781,"marketCap":81752380},{"date":"2022-11-25","current":3.264743,"twenty":-0.281646,"median":2.900263,"eighty":22.039781,"marketCap":82774284},{"date":"2022-12-02","current":3.208315,"twenty":-0.278938,"median":2.909515,"eighty":22.039781,"marketCap":81343618},{"date":"2022-12-09","current":3.027746,"twenty":0.690334,"median":2.920572,"eighty":22.023194,"marketCap":76765484},{"date":"2022-12-16","current":2.937462,"twenty":1.319576,"median":2.928984,"eighty":21.985873,"marketCap":74476418},{"date":"2022-12-23","current":2.498939,"twenty":1.458571,"median":2.923052,"eighty":21.878059,"marketCap":63358094},{"date":"2022-12-30","current":2.663385,"twenty":1.56152,"median":2.918116,"eighty":21.803418,"marketCap":67527465},{"date":"2023-01-06","current":2.889096,"twenty":1.56152,"median":2.920572,"eighty":21.803418,"marketCap":73250132},{"date":"2023-01-13","current":3.121255,"twenty":1.56152,"median":2.934238,"eighty":21.803418,"marketCap":79136303},{"date":"2023-01-20","current":3.163173,"twenty":1.56152,"median":2.940687,"eighty":21.803418,"marketCap":80199084},{"date":"2023-01-27","current":3.03742,"twenty":1.56152,"median":2.963813,"eighty":21.803418,"marketCap":77010741},{"date":"2023-02-03","current":3.089011,"twenty":1.56152,"median":2.97938,"eighty":21.803418,"marketCap":78318780},{"date":"2023-02-10","current":2.995502,"twenty":1.56152,"median":2.986046,"eighty":21.803418,"marketCap":75947961},{"date":"2023-02-17","current":3.069664,"twenty":1.56152,"median":2.995967,"eighty":21.803418,"marketCap":77828265},{"date":"2023-02-24","current":3.101909,"twenty":1.56152,"median":3.006318,"eighty":21.803418,"marketCap":78645789},{"date":"2023-03-03","current":7.166438,"twenty":1.56152,"median":3.021298,"eighty":21.803418,"marketCap":76129066},{"date":"2023-03-10","current":6.673589,"twenty":1.565877,"median":3.03742,"eighty":21.803418,"marketCap":70893541},{"date":"2023-03-17","current":6.627828,"twenty":1.596379,"median":3.047969,"eighty":21.803418,"marketCap":70407414},{"date":"2023-03-24","current":7.581198,"twenty":1.601086,"median":3.061417,"eighty":21.803418,"marketCap":80535062},{"date":"2023-03-31","current":7.413404,"twenty":1.645072,"median":3.077506,"eighty":21.786831,"marketCap":78752596},{"date":"2023-04-06","current":7.192223,"twenty":1.601086,"median":3.08741,"eighty":21.803418,"marketCap":76402982},{"date":"2023-04-14","current":7.390524,"twenty":1.5571,"median":3.105133,"eighty":21.820005,"marketCap":78509533},{"date":"2023-04-21","current":7.375972,"twenty":1.513114,"median":3.121255,"eighty":21.836592,"marketCap":78354950},{"date":"2023-04-28","current":6.610326,"twenty":1.469128,"median":3.128557,"eighty":21.853179,"marketCap":70221497},{"date":"2023-05-05","current":6.094842,"twenty":1.469128,"median":3.146532,"eighty":21.853179,"marketCap":64745508},{"date":"2023-05-12","current":6.315875,"twenty":1.469128,"median":3.161027,"eighty":21.853179,"marketCap":69335675},{"date":"2023-05-19","current":6.24252,"twenty":1.469128,"median":3.171711,"eighty":21.853179,"marketCap":68530383},{"date":"2023-05-26","current":5.892774,"twenty":1.469128,"median":3.174891,"eighty":21.853179,"marketCap":64690871},{"date":"2023-06-02","current":6.111565,"twenty":1.469128,"median":3.178756,"eighty":21.853179,"marketCap":67092760},{"date":"2023-06-09","current":6.149999,"twenty":1.469128,"median":3.189323,"eighty":21.853179,"marketCap":67514692},{"date":"2023-06-16","current":6.082393,"twenty":1.469128,"median":3.199227,"eighty":21.853179,"marketCap":66772508},{"date":"2023-06-23","current":6.049574,"twenty":1.458571,"median":3.208315,"eighty":21.878059,"marketCap":66412225},{"date":"2023-06-30","current":6.257426,"twenty":1.448015,"median":3.216397,"eighty":21.902939,"marketCap":68694019},{"date":"2023-07-07","current":6.250133,"twenty":1.448015,"median":3.224292,"eighty":21.902939,"marketCap":68613956},{"date":"2023-07-14","current":6.578319,"twenty":1.448015,"median":3.243521,"eighty":21.902939,"marketCap":72216789},{"date":"2023-07-21","current":6.702301,"twenty":1.448015,"median":3.24834,"eighty":21.902939,"marketCap":73577860},{"date":"2023-07-28","current":6.578319,"twenty":1.448015,"median":3.264991,"eighty":21.902939,"marketCap":72216789},{"date":"2023-08-04","current":6.184495,"twenty":1.448015,"median":3.286333,"eighty":21.902939,"marketCap":67893390},{"date":"2023-08-11","current":6.351685,"twenty":1.448015,"median":3.322273,"eighty":21.902939,"marketCap":70535467},{"date":"2023-08-18","current":6.122833,"twenty":1.448015,"median":3.390097,"eighty":21.902939,"marketCap":67994059},{"date":"2023-08-25","current":6.050115,"twenty":1.448015,"median":3.429194,"eighty":21.902939,"marketCap":67186529},{"date":"2023-09-01","current":6.166463,"twenty":1.448015,"median":3.730203,"eighty":21.902939,"marketCap":68478577},{"date":"2023-09-08","current":5.810147,"twenty":1.448015,"median":3.743573,"eighty":21.902939,"marketCap":64521678},{"date":"2023-09-15","current":6.006485,"twenty":1.448015,"median":3.764583,"eighty":21.902939,"marketCap":66702011},{"date":"2023-09-22","current":5.868321,"twenty":1.448015,"median":4.024697,"eighty":21.902939,"marketCap":65167703},{"date":"2023-09-29","current":5.991941,"twenty":1.448015,"median":4.078921,"eighty":21.902939,"marketCap":66540504},{"date":"2023-10-06","current":5.970126,"twenty":1.448015,"median":4.113063,"eighty":21.902939,"marketCap":66298245},{"date":"2023-10-13","current":5.82469,"twenty":1.448015,"median":4.135155,"eighty":21.902939,"marketCap":64683185},{"date":"2023-10-20","current":5.263018,"twenty":1.448015,"median":4.142325,"eighty":21.902939,"marketCap":58445820},{"date":"2023-10-27","current":5.453103,"twenty":1.416345,"median":4.14118,"eighty":21.97758,"marketCap":60556704},{"date":"2023-11-03","current":5.639187,"twenty":1.416345,"median":4.14118,"eighty":14.071633,"marketCap":62623174},{"date":"2023-11-10","current":4.597236,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60968545},{"date":"2023-11-17","current":4.691483,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":62218453},{"date":"2023-11-24","current":4.594442,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60931496},{"date":"2023-12-01","current":4.552014,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60368804},{"date":"2023-12-08","current":5.091467,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":67523030},{"date":"2023-12-15","current":5.430898,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":72024565},{"date":"2023-12-22","current":6.121882,"twenty":1.426902,"median":4.144334,"eighty":13.959496,"marketCap":81188405},{"date":"2023-12-29","current":5.921861,"twenty":1.416345,"median":4.173313,"eighty":13.99376,"marketCap":78535715},{"date":"2024-01-05","current":5.994596,"twenty":1.319576,"median":4.201799,"eighty":14.009335,"marketCap":79500329},{"date":"2024-01-12","current":6.030963,"twenty":1.319576,"median":4.247621,"eighty":14.009335,"marketCap":79982637},{"date":"2024-01-19","current":5.897615,"twenty":1.222807,"median":4.282189,"eighty":14.024909,"marketCap":78214176},{"date":"2024-01-26","current":5.909738,"twenty":1.319576,"median":4.311888,"eighty":14.009335,"marketCap":78374946},{"date":"2024-02-02","current":6.079454,"twenty":1.319576,"median":4.327955,"eighty":14.009335,"marketCap":80625713},{"date":"2024-02-09","current":5.976412,"twenty":1.319576,"median":4.350046,"eighty":14.009335,"marketCap":79259176},{"date":"2024-02-16","current":6.085515,"twenty":1.319576,"median":4.362096,"eighty":14.009335,"marketCap":80706098},{"date":"2024-02-23","current":6.321904,"twenty":1.319576,"median":4.386196,"eighty":14.009335,"marketCap":83841096},{"date":"2024-03-01","current":6.697703,"twenty":1.416345,"median":4.576259,"eighty":13.99376,"marketCap":88824938},{"date":"2024-03-08","current":3.802021,"twenty":1.416345,"median":4.594442,"eighty":13.99376,"marketCap":85127249},{"date":"2024-03-15","current":3.670771,"twenty":1.416345,"median":4.552014,"eighty":13.627758,"marketCap":82188558},{"date":"2024-03-22","current":4.518879,"twenty":1.416345,"median":4.374799,"eighty":13.542097,"marketCap":101177708},{"date":"2024-03-28","current":4.473036,"twenty":1.416345,"median":4.324209,"eighty":13.253968,"marketCap":100151267},{"date":"2024-04-05","current":4.548166,"twenty":1.319576,"median":4.316791,"eighty":13.048383,"marketCap":101833436},{"date":"2024-04-12","current":4.421557,"twenty":1.319576,"median":4.316791,"eighty":12.951821,"marketCap":98998672},{"date":"2024-04-19","current":4.434543,"twenty":1.319576,"median":4.316791,"eighty":12.824109,"marketCap":99289417},{"date":"2024-04-26","current":4.434543,"twenty":1.416345,"median":4.324209,"eighty":12.732219,"marketCap":99289417},{"date":"2024-05-03","current":4.212125,"twenty":1.416345,"median":4.309328,"eighty":12.514175,"marketCap":94309475},{"date":"2024-05-10","current":3.932803,"twenty":1.416345,"median":4.212125,"eighty":12.280556,"marketCap":98662220},{"date":"2024-05-17","current":3.918344,"twenty":1.416345,"median":4.14347,"eighty":12.078087,"marketCap":98299491},{"date":"2024-05-24","current":3.756405,"twenty":1.416345,"median":3.988402,"eighty":12.000214,"marketCap":94236929},{"date":"2024-05-31","current":3.606033,"twenty":1.416345,"median":3.918344,"eighty":11.314932,"marketCap":90464550},{"date":"2024-06-07","current":3.788005,"twenty":1.416345,"median":3.860508,"eighty":9.717873,"marketCap":95029691},{"date":"2024-06-14","current":3.851139,"twenty":1.319576,"median":3.804358,"eighty":7.887548,"marketCap":96613519},{"date":"2024-06-21","current":3.893228,"twenty":1.222807,"median":3.802673,"eighty":7.521707,"marketCap":97669405},{"date":"2024-06-28","current":3.839113,"twenty":0.932501,"median":3.800901,"eighty":7.413404,"marketCap":96311838},{"date":"2024-07-05","current":3.953355,"twenty":0.932501,"median":3.800901,"eighty":7.375972,"marketCap":99177812},{"date":"2024-07-12","current":4.109685,"twenty":0.932501,"median":3.800901,"eighty":7.207477,"marketCap":103099673},{"date":"2024-07-15","current":4.193863,"twenty":0.932501,"median":3.800901,"eighty":7.194036,"marketCap":105211444},{"date":"2024-08-02","current":4.458422,"twenty":-0.282248,"median":3.785593,"eighty":6.893892,"marketCap":111848438},{"date":"2024-08-09","current":4.330188,"twenty":-0.282248,"median":3.785593,"eighty":6.71397,"marketCap":112034952},{"date":"2024-08-16","current":4.293515,"twenty":-0.282248,"median":3.785593,"eighty":6.684421,"marketCap":111086122},{"date":"2024-08-23","current":4.437385,"twenty":-0.282248,"median":3.785593,"eighty":6.626684,"marketCap":114808456},{"date":"2024-08-30","current":4.443027,"twenty":-0.282248,"median":3.785593,"eighty":6.593741,"marketCap":114954430},{"date":"2024-09-06","current":4.420459,"twenty":-0.282248,"median":3.785593,"eighty":6.572485,"marketCap":114370534},{"date":"2024-09-13","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.489344,"marketCap":112764822},{"date":"2024-09-20","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.439122,"marketCap":112764822},{"date":"2024-09-27","current":4.403533,"twenty":-0.282248,"median":3.785593,"eighty":6.403286,"marketCap":113932613},{"date":"2024-10-04","current":4.45149,"twenty":-0.282248,"median":3.785593,"eighty":6.389947,"marketCap":115173391},{"date":"2024-10-11","current":4.474057,"twenty":-0.282248,"median":3.785593,"eighty":6.366105,"marketCap":115757286},{"date":"2024-10-18","current":4.327367,"twenty":-0.282248,"median":3.785593,"eighty":6.321904,"marketCap":111961965},{"date":"2024-10-25","current":4.321725,"twenty":-0.282248,"median":3.785593,"eighty":6.261802,"marketCap":111815992},{"date":"2024-10-31","current":4.27941,"twenty":-0.282248,"median":3.785593,"eighty":6.240491,"marketCap":110721187},{"date":"2024-11-08","current":4.441959,"twenty":-0.282549,"median":3.784012,"eighty":6.202291,"marketCap":116779104},{"date":"2024-11-15","current":4.397133,"twenty":-0.282549,"median":3.784012,"eighty":6.149605,"marketCap":115600635},{"date":"2024-11-22","current":4.560596,"twenty":-0.282549,"median":3.784012,"eighty":6.139391,"marketCap":119898057},{"date":"2024-11-29","current":4.732231,"twenty":-0.282549,"median":3.784012,"eighty":6.120618,"marketCap":124410349},{"date":"2024-12-06","current":4.80034,"twenty":-0.282549,"median":3.784012,"eighty":6.102487,"marketCap":126200941},{"date":"2024-12-13","current":4.66957,"twenty":-0.282549,"median":3.784012,"eighty":6.088852,"marketCap":122763004},{"date":"2024-12-20","current":4.171011,"twenty":-0.282549,"median":3.784012,"eighty":6.078382,"marketCap":109655869},{"date":"2024-12-27","current":4.405306,"twenty":-0.282549,"median":3.784012,"eighty":6.067331,"marketCap":115815506},{"date":"2025-01-03","current":4.489762,"twenty":-0.282549,"median":3.784012,"eighty":6.059453,"marketCap":118035841},{"date":"2025-01-10","current":4.745853,"twenty":-0.28285,"median":3.782431,"eighty":6.049147,"marketCap":124768467},{"date":"2025-01-17","current":4.822135,"twenty":-0.28285,"median":3.782431,"eighty":6.037025,"marketCap":126773931},{"date":"2025-01-24","current":4.890244,"twenty":-0.28285,"median":3.782431,"eighty":6.035572,"marketCap":128564523},{"date":"2025-01-31","current":4.794891,"twenty":-0.28285,"median":3.782431,"eighty":6.016756,"marketCap":126057694},{"date":"2025-02-07","current":5.012841,"twenty":-0.28285,"median":3.782431,"eighty":6.002169,"marketCap":131787589},{"date":"2025-02-14","current":5.165406,"twenty":-0.28285,"median":3.782431,"eighty":5.999213,"marketCap":135798516},{"date":"2025-02-21","current":5.375182,"twenty":-0.28285,"median":3.782431,"eighty":5.991941,"marketCap":141313540},{"date":"2025-02-28","current":5.6231,"twenty":-0.28285,"median":3.782431,"eighty":5.970126,"marketCap":147831296},{"date":"2025-03-07","current":5.080493,"twenty":-0.283753,"median":3.782268,"eighty":5.951081,"marketCap":148690780},{"date":"2025-03-14","current":5.481842,"twenty":-0.283753,"median":3.782268,"eighty":5.922788,"marketCap":160437065},{"date":"2025-03-21","current":11.366901,"twenty":-0.283753,"median":3.788005,"eighty":5.926495,"marketCap":332675095},{"date":"2025-03-28","current":5.041233,"twenty":-0.283753,"median":3.800901,"eighty":5.92678,"marketCap":147541761},{"date":"2025-04-04","current":4.869586,"twenty":-0.283753,"median":3.829511,"eighty":5.92678,"marketCap":142518184},{"date":"2025-04-11","current":4.150082,"twenty":-0.28285,"median":3.860508,"eighty":5.926495,"marketCap":121460451},{"date":"2025-04-17","current":4.12892,"twenty":-0.28285,"median":3.878196,"eighty":5.926495,"marketCap":120841106}],"updateTime":1745134601577}}}